Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Medtronic
AstraZeneca
McKesson
Mallinckrodt

Last Updated: December 11, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,513,255

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 8,513,255 protect, and when does it expire?

Patent 8,513,255 protects PREVYMIS and is included in two NDAs.

This patent has forty-four patent family members in thirty-six countries.

Summary for Patent: 8,513,255
Title:Substituted dihydroquinazolines
Abstract: The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.
Inventor(s): Wunberg; Tobias (Hinterbruehl, AT), Baumeister; Judith (Mechelen, BE), Betz; Ulrich (Reinheim, DE), Jeske; Mario (Solingen, DE), Lampe; Thomas (Duesseldorf, DE), Nikolic; Susanne (Monheim, DE), Reefschlaeger; Juergen (Oldenburg, DE), Schohe-Loop; Rudolf (Wuppertal, DE), Suessmeier; Frank (Wuppertal, DE), Zimmermann; Holger (Wuppertal, DE), Grosser; Rolf (Leverkusen, DE), Henninger; Kerstin (Wuppertal, DE), Hewlett; Guy (Haan, DE), Keldenich; Joerg (Wuppertal, DE), Lang; Dieter (Velbert, DE), Nell; Peter (Wuppertal, DE)
Assignee: AiCuris GmbH + Co. KG. (Wuppertal, DE)
Application Number:11/728,896
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Process;

Drugs Protected by US Patent 8,513,255

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Merck Sharp Dohme PREVYMIS letermovir SOLUTION;INTRAVENOUS 209940-001 Nov 8, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Merck Sharp Dohme PREVYMIS letermovir SOLUTION;INTRAVENOUS 209940-002 Nov 8, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Merck Sharp Dohme PREVYMIS letermovir TABLET;ORAL 209939-001 Nov 8, 2017 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Merck Sharp Dohme PREVYMIS letermovir TABLET;ORAL 209939-002 Nov 8, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,513,255

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany103 19 612May 2, 2003

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Mallinckrodt
Johnson and Johnson
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.